Drug Delivery Technologies Market Forecast 2015-2025: Prospects for Leading Companies

USA - English

• USA - Français

LONDON, July 17, 2015 /PRNewswire/ --

Drug Delivery Technology - assess products, developments, and revenue prospects
What does the future hold for the drug delivery technologies market? Visiongain's brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects.
Our 204 page report provides 113 tables, charts, and graphs covering 6 leading and distinct submarkets. Discover the most lucrative areas in the industry and the future market prospects. You will see financial results, interviews, trends, opportunities, and revenue predictions. Increasing development and use of biological drugs (biologics) will increase worldwide sales of drug delivery technologies from 2015 to 2025, our study shows.

Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. You will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT), company profiles and commercial developments. Read the full transcript of 5 exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
- Dr Igor Gonda, President and CEO & David Cipolla, Senior Director of Pharmaceutical Sciences, Aradigm
- Dr Claus Michael Lehr, Head of Department, Drug Delivery at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)
- Dr. Bridget Martell, Chief Medical Officer and Vice President of Clinical Product Development, Juniper Pharmaceuticals
- John McCarter, Director of Business Development, Soluble Therapeutics
- Dr Sven Frokjaer, Dean and Professor of Pharmaceutical Sciences, University of Copenhagen, Denmark



To see a report overview please email Sara Peerun on [email protected]
You will find prospects for key submarkets
In addition to analyses of the overall world market, you will see revenue forecasting of 6 major submarkets to 2025:
• Oral Drug Delivery Market Forecast 2015-2025
• Inhalable Drug Delivery Market Forecast 2015-2025
• Injectable/Implantable Drug Delivery Market Forecast 2015-2025
• Transdermal Drug Delivery Market Forecast 2015-2025
• Ocular Drug Delivery Market Forecast 2015-2025
• Nasal/Buccal Drug Delivery Market Forecast 2015-2025
Our new study also provides qualitative analyses for each submarket identifying strengths, weaknesses, opportunities and potential threats to sales growth.
How will those drug delivery markets expand? Which applications will generate the most money? This study will allow you to thoroughly understand the industry, finding the most promising places for investments and sales.
What are the prospects in the leading regions and countries?
In our study you will find individual revenue forecasts to 2025 for the leading regional and national markets:
• US
• Japan
• Germany
• France
• UK
• Spain
• Italy
• China
• India
• Brazil
• Russia
• South Korea
• Mexico
• Rest of the World
Many opportunities exist within the drug delivery technologies market. With our new investigation you will gain business research and analysis with individual sales predictions and discussions. You will find analysis of competition, as well as commercial drivers and restraints.


To see a report overview please email Sara Peerun on [email protected]
Leading companies and potential for market growth
Overall world revenue for the drug delivery technologies market will reach $159.3bn in 2015, our work forecasts. We predict strong revenue growth from 2015 to 2025. Our work shows you what organisations hold greatest potential. See profiles of 10 leading companies and others, including:
• Alkermes
• 3M
• Skyepharma
• BD
• Antares Pharma
• pSivida
• Applied Pharma Research
• Ethypharm
• Glycologic
• NanoPass Technologies
In general, a company profile gives you the following information:
• Overview of the company, including its history in the drug delivery technology market
• Discussion of a company's activities and outlook including descriptions of leading products
• Recent financial results
• Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations, inc. alliances, partnerships and joint ventures
What issues will affect the drug delivery technology market?
Our new report discusses issues and events affecting the drug delivery technology market. You will find discussions, including qualitative analyses:
• Product life cycle extension
• The strong growth of biologics
• Trends toward self administration
• Aging population
• Rising incidence of chronic diseases such as diabetes
Technologies and applications giving improved clinical efficacy, patient convenience and treatment compliance will achieve success. In particular, greater use of injectable drugs and vaccines worldwide will stimulate demand for innovative delivery systems.
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.



How the Drug Delivery Technologies Market Forecast 2015-2025: Prospects for Leading Companies report helps you
In summary, our 204 page report gives you the following knowledge:
• Revenue forecasts to 2025 for the overall world drug delivery technology market and 6 submarkets - discover the industry's prospects, finding promising places for investments and revenues
• Assessment of leading companies, and others, discovering activities and outlooks
• Market forecasting to 2025 for the leading regional and national markets - US, Japan, Germany, France, UK, Spain, Italy, China, India, Brazil, Russia, South Korea, Mexico and RoW
• View opinions from our survey, seeing interviews with authorities
• Investigation of competition and opportunities influencing sales
• Discussion of what stimulates and restrains the drug delivery technology market
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the drug delivery technologies market. You find data, trends and predictions. Please order our report now.

To see a report overview please email Sara Peerun on [email protected]

To request an exec summary of this report please email Sara Peerun at [email protected] or call Tel: +44 (0) 20 7336 6100
Or click on https://goo.gl/FOH6zr



Companies Mentioned in This Report
3M
Acorda
Actavis
Adamis
Aleza Pharmaceuticals
Alkermes
Almirall
Alza
Antares Pharma
Applied Pharma Research
Aradigm
Astellas
AstraZeneca
Bayer HealthCare Pharmaceuticals
BD
Biogen
BioGeneration Ventures
Bioject Medical Technologies
Boehringer Ingelheim
Bristol¬Myers Squibb
CareFusion Corporation
Cephalon
Changchun BCHT
Chiesi
Cilag
Cima Labs
Clearside
Cosmo Pharmaceuticals
CRISI Medical Systems
CTCBIO
Daiichi
Elan Drug Technologies
Elcam Medical
Eli Lilly
Ethypharm
Ferring
Flamel
Genentech
GlaxoSmithKline
Glycologic
Google
GSK
Haselmeir
Horizon Pharma
ImmusanT
Innovent Biologics
Insmed
Invion
iScience Interventional Corporation
J&J
Janssen
JCR Pharmaceuticals
Kyorin
MannKind
Meda Pharmaceuticals
Medac
Medimetrics
MedImmune
MedSciences Capital
Merck Serono
Mucosis
Mundipharma
Nanopass Technologies
Nektar Therapeutics
Nexvax2
NHTherapeutics
Novartis
Novo Nordisk
NuPathe
NV NOM
OwenMumford
Pacira Pharmaceuticals
Pari Pharma
Permatec
Pfizer
PharmaJet
Presspart
ProStrakan
pSivida
Pulmagen
Ranbaxy
Rani Therapeutics
Recro Pharma
Regeneron Pharmaceuticals
Roche
Sandoz
Sanofi-Aventis
Santen
Shionogi
SHL Group
Shreya Life Sciences
Skyepharma
Smoofi
Spark Therapeutics
STADA Arzneimittel
Takeda
Teva
UU Holdings
Vetter Pharma
West Pharmaceuticals
Ypsomed

Organisations Mentioned in This Report
Emory University School of Medicine
Georgia Institute of Technology
Hospital for Special Surgery
University of Oxford

SOURCE Visiongain